Cargando…

A blood-based gene expression and signaling pathway analysis to differentiate between high and low grade gliomas

The aims of the present study were to undertake gene expression profiling of the blood of glioma patients to determine key genetic components of signaling pathways and to develop a panel of genes that could be used as a potential blood-based biomarker to differentiate between high and low grade glio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponnampalam, Stephen N., Kamaluddin, Nor Rizan, Zakaria, Zubaidah, Matheneswaran, Vickneswaran, Ganesan, Dharmendra, Haspani, Mohammed Saffari, Ryten, Mina, Hardy, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355666/
https://www.ncbi.nlm.nih.gov/pubmed/28004117
http://dx.doi.org/10.3892/or.2016.5285
_version_ 1782515627266670592
author Ponnampalam, Stephen N.
Kamaluddin, Nor Rizan
Zakaria, Zubaidah
Matheneswaran, Vickneswaran
Ganesan, Dharmendra
Haspani, Mohammed Saffari
Ryten, Mina
Hardy, John A.
author_facet Ponnampalam, Stephen N.
Kamaluddin, Nor Rizan
Zakaria, Zubaidah
Matheneswaran, Vickneswaran
Ganesan, Dharmendra
Haspani, Mohammed Saffari
Ryten, Mina
Hardy, John A.
author_sort Ponnampalam, Stephen N.
collection PubMed
description The aims of the present study were to undertake gene expression profiling of the blood of glioma patients to determine key genetic components of signaling pathways and to develop a panel of genes that could be used as a potential blood-based biomarker to differentiate between high and low grade gliomas, non-gliomas and control samples. In this study, blood samples were obtained from glioma patients, non-glioma and control subjects. Ten samples each were obtained from patients with high and low grade tumours, respectively, ten samples from non-glioma patients and twenty samples from control subjects. Total RNA was isolated from each sample after which first and second strand synthesis was performed. The resulting cRNA was then hybridized with the Agilent Whole Human Genome (4×44K) microarray chip according to the manufacturer's instructions. Universal Human Reference RNA and samples were labeled with Cy3 CTP and Cy5 CTP, respectively. Microarray data were analyzed by the Agilent Gene Spring 12.1V software using stringent criteria which included at least a 2-fold difference in gene expression between samples. Statistical analysis was performed using the unpaired Student's t-test with a P<0.01. Pathway enrichment was also performed, with key genes selected for validation using droplet digital polymerase chain reaction (ddPCR). The gene expression profiling indicated that were a substantial number of genes that were differentially expressed with more than a 2-fold change (P<0.01) between each of the four different conditions. We selected key genes within significant pathways that were analyzed through pathway enrichment. These key genes included regulators of cell proliferation, transcription factors, cytokines and tumour suppressor genes. In the present study, we showed that key genes involved in significant and well established pathways, could possibly be used as a potential blood-based biomarker to differentiate between high and low grade gliomas, non-gliomas and control samples.
format Online
Article
Text
id pubmed-5355666
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-53556662017-03-31 A blood-based gene expression and signaling pathway analysis to differentiate between high and low grade gliomas Ponnampalam, Stephen N. Kamaluddin, Nor Rizan Zakaria, Zubaidah Matheneswaran, Vickneswaran Ganesan, Dharmendra Haspani, Mohammed Saffari Ryten, Mina Hardy, John A. Oncol Rep Articles The aims of the present study were to undertake gene expression profiling of the blood of glioma patients to determine key genetic components of signaling pathways and to develop a panel of genes that could be used as a potential blood-based biomarker to differentiate between high and low grade gliomas, non-gliomas and control samples. In this study, blood samples were obtained from glioma patients, non-glioma and control subjects. Ten samples each were obtained from patients with high and low grade tumours, respectively, ten samples from non-glioma patients and twenty samples from control subjects. Total RNA was isolated from each sample after which first and second strand synthesis was performed. The resulting cRNA was then hybridized with the Agilent Whole Human Genome (4×44K) microarray chip according to the manufacturer's instructions. Universal Human Reference RNA and samples were labeled with Cy3 CTP and Cy5 CTP, respectively. Microarray data were analyzed by the Agilent Gene Spring 12.1V software using stringent criteria which included at least a 2-fold difference in gene expression between samples. Statistical analysis was performed using the unpaired Student's t-test with a P<0.01. Pathway enrichment was also performed, with key genes selected for validation using droplet digital polymerase chain reaction (ddPCR). The gene expression profiling indicated that were a substantial number of genes that were differentially expressed with more than a 2-fold change (P<0.01) between each of the four different conditions. We selected key genes within significant pathways that were analyzed through pathway enrichment. These key genes included regulators of cell proliferation, transcription factors, cytokines and tumour suppressor genes. In the present study, we showed that key genes involved in significant and well established pathways, could possibly be used as a potential blood-based biomarker to differentiate between high and low grade gliomas, non-gliomas and control samples. D.A. Spandidos 2017-01 2016-11-29 /pmc/articles/PMC5355666/ /pubmed/28004117 http://dx.doi.org/10.3892/or.2016.5285 Text en Copyright: © Ponnampalam et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Ponnampalam, Stephen N.
Kamaluddin, Nor Rizan
Zakaria, Zubaidah
Matheneswaran, Vickneswaran
Ganesan, Dharmendra
Haspani, Mohammed Saffari
Ryten, Mina
Hardy, John A.
A blood-based gene expression and signaling pathway analysis to differentiate between high and low grade gliomas
title A blood-based gene expression and signaling pathway analysis to differentiate between high and low grade gliomas
title_full A blood-based gene expression and signaling pathway analysis to differentiate between high and low grade gliomas
title_fullStr A blood-based gene expression and signaling pathway analysis to differentiate between high and low grade gliomas
title_full_unstemmed A blood-based gene expression and signaling pathway analysis to differentiate between high and low grade gliomas
title_short A blood-based gene expression and signaling pathway analysis to differentiate between high and low grade gliomas
title_sort blood-based gene expression and signaling pathway analysis to differentiate between high and low grade gliomas
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355666/
https://www.ncbi.nlm.nih.gov/pubmed/28004117
http://dx.doi.org/10.3892/or.2016.5285
work_keys_str_mv AT ponnampalamstephenn abloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT kamaluddinnorrizan abloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT zakariazubaidah abloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT matheneswaranvickneswaran abloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT ganesandharmendra abloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT haspanimohammedsaffari abloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT rytenmina abloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT hardyjohna abloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT ponnampalamstephenn bloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT kamaluddinnorrizan bloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT zakariazubaidah bloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT matheneswaranvickneswaran bloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT ganesandharmendra bloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT haspanimohammedsaffari bloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT rytenmina bloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas
AT hardyjohna bloodbasedgeneexpressionandsignalingpathwayanalysistodifferentiatebetweenhighandlowgradegliomas